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Abstract
Background: For ethical approval of a multicentre study in Canada, investigators must apply separately to
individual Research Ethics Boards (REBs). In principle, the protection of human research subjects is of utmost
importance. However, in practice, the process of multicentre ethics review can be time consuming and costly,
requiring duplication of effort for researchers and REBs. We used our experience with ethical review of The
Canadian Perinatal Network (CPN), to gain insight into the Canadian system.
Methods: The applications forms of 16 different REBs were abstracted for a list of standardized items. The
application process across sites was compared. Correspondence between the REB and the investigators was
documented in order to construct a timeline to approval, identify the specific issues raised by each board, and
describe how they were resolved.
Results: Each REB had a different application form. Most (n = 9) had a two or three step application process.
Overall, it took a median of 31 days (range 2-174 days) to receive an initial response from the REB. Approval took a
median of 42 days (range 4-443 days). Privacy and consent were the two major issues raised. Several additional
minor or administrative issues were raised which delayed approval.
Conclusions: For CPN, the Canadian REB process of ethical review proved challenging. REBs acted independently
and without unified application forms or submission procedures. We call for a critical examination of the ethical,
privacy and institutional review processes in Canada, to determine the best way to undertake multicentre review.
Background
Ethics review of research involving human subjects is
essential to protect the rights and safety of research sub-
jects [1], by promoting socially beneficial research, pro-
tecting human subjects from harm and indignity, and
maintaining trust between researchers and society [2].
In Canada, the Tri-Council Policy Statement (TCPS),
“Ethical Conduct for Research Involving Humans“ estab-
lishes a common policy of ethical conduct for research
based on fundamental ethical principles [3]. Local
research ethics boards (REBs) are responsible for review-
ing research protocols at the institutional level, accord-
ing to TCPS definitions of REB composition and
function. This model is ideally suited to single centre
research studies conducted by investigators based in
that centre. However, multicentre collaborative research
has become increasingly common [1,4,5], and local
ethics review of multicentre studies has been criticised
because it is time consuming and costly (for REBs and
investigators), duplicates review effort, and has no dis-
cernible impact on improving patient safety [1,2,5,6].
Local review is further complicated by the need for
review of institution-specific requirements, for example
availability of institutional resources necessary for the
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research, and the requirements of provincial privacy leg-
islation. In addition, some institutions require separate
scientific review. The lack of standardized institutional
review across Canada has complicated the review of
multicentre research [6]. Many researchers have
expressed frustration with the process and questioned
its effectiveness [4]. Variability in ethics review has been
documented in various settings [5], such as multicentre
clinical trials [6-8], genetic epidemiology [9], and in
both mailed and telephone survey research [10-13], but
not in the context of database research where the pri-
mary concern is privacy, rather than specific issues of
informed consent.
In 2005, the Canadian Institutes of Health Research
(CIHR) funded the Canadian Perinatal Network (CPN)
to develop a national database in Canada’s 23 tertiary
perinatal units. The objective of CPN is to improve
quality of care by identifying best obstetric practices.
The inaugural project examines threatened preterm
birth. We evaluated CPN investigators’ experiences with
local institutional approval procedure to gain insight
into the Canadian multicentre ethics review process for
a database study, and to learn specifically how ethics
review process is undertaken locally.
Methods
CPN collects data, by chart review of maternal and fetal
records, on all women who are admitted to a participat-
ing tertiary perinatal unit at 220-286 weeks’ gestation
with threatened very preterm delivery. Personal identi-
fiers are stripped during electronic data transfer to a
central computerized database at the CPN Co-ordinat-
ing Centre, Vancouver.
From 2005-8, 16 tertiary care academic Canadian hos-
pitals applied for REB approval for CPN. The protocol
was unchanged over this time period. We obtained a
complete file of REB applications and all correspon-
dence between the CPN investigators, their local REB
and the CPN Co-ordinating Centre. We did not contact
REBs directly as we were not named on the relevant
applications. LM (CPN co-principal investigator) and
HE (Obstetrics and Gynaecology resident) independently
constructed a timeline from submission to acceptance
by the REB, catalogued the standardized content of each
REB’s application form and compiled a list of specific
issues that the individual site investigator was asked to
address by the REB. LM and HE were both at arms
length from the REB process, other than the site-specific
application at BC Women’s Hospital (by LM): the new
CPN Co-ordinator (TM) who was not involved in this
application reviewed the BC Women’s data for this ana-
lysis. Disagreement between reviewers was resolved by
discussion and consensus.
We focused on issues of relevance to database
research, determined a priori and identified in Sections
2 and 3 of the TCPS [3]: waiver of consent, accessing
identifiable private information from hospital charts,
appropriate safeguards for security and confidentiality
(including data storage and destruction), confidentiality
of reported data, and obtaining and linking data from
several sources.
Results
The number of steps involved in the initial application
was not consistent across sites. Four sites had a one-
step process involving only local REB application. Nine
sites required an additional step of either local hospital
or administrative approval. Three sites had a third step
consisting of either separate scientific review before REB
approval plus local hospital review, or REB, hospital plus
other administrative or operational approval. In addi-
tion, six sites required sign-off by an additional depart-
ment (information technology [IT] (n = 2), data access
office (n = 1), privacy committee (n = 2), and/or com-
munication department (n = 1). Five sites required sepa-
rate health records approval. Two sites in different
provinces involved a provincial privacy office but in
both cases, those offices indicated that their involvement
was unnecessary as patient protection fell to the hospi-
tal. At two sites, the IT department held up network
installation of the database because of privacy concerns
previously addressed by their local REB, resulting in
delays of up to seven months.
Fifteen sites had an application form (all different)
with specific questions asked. These questions are pre-
sented in Table 1. Three of 15 had specific forms for
chart review or database studies; one site had a list of
subheadings indicating the items to be addressed. Three
of 15 sites asked about review by another REB. One site
asked about previous peer review. All sites gathered
basic information (e.g., investigator contact details).
Fourteen sites asked about the sample size, method of
patient selection, time period of the study, and funding
source (which at one site was only whether the study
was industry sponsored). Consent was a subheading or a
question asked by all sites but with various levels of
detail; six sites (40%) asked investigators to justify why
the requirement for informed consent was waived if
consent was not obtained (as for CPN).
Table 2 shows that only some sites asked specific
questions about data handling and privacy protection
(although questions were later added to the form at one
site). Six sites (40%) asked for a general description of
privacy measures or for an assurance of confidentiality.
There was no apparent relationship between the form
version date and the detail requested.
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Overall, it took a median [range] of 42 days [4-443] to
receive final REB approval. When CPN underwent expe-
dited review (n = 9), the median time to approval was
33 days [8-239]. When local hospital approval was given
separately from REB approval, the additional median
time to approval was 32 days [4-197]. Ten REBs had no
issues with the proposal: their median time to approval
was 33 days [8-251]. For the site which required 251
days to receive approval despite no ethical concerns,
REB approval took 54 days, but then local hospital
approval took a further 197 days. Six REBs requested
more information: their median time to approval was
178 days [55-443].
When more information was requested, one REB (of 10
that did not ask the question routinely) asked the investi-
gators to justify why informed consent should be waived
for CPN. Three sites had concerns about privacy beyond
what was covered in the application: whether identifiers
were recorded (n = 4), clarification regarding who had
access to the data (n = 2), location of data storage (n = 1),
future use of data (n = 2), and technical concerns about
database operation (n = 1). Two of the sites were based
within the same province: one REB approved the protocol,
while the other said that CPN needed approval from the
provincial privacy office until the previous REB’s approval
was brought to their attention. Other issues raised were:
administrative issues including the need for additional sig-
natures (n = 2); insufficient salary for the research assistant
(n = 1); and grammatical, spelling, or layout issues with
the patient information pamphlet (n = 2). One site raised
a new issue each time the previous issue was addressed,
requiring six different responses.
Discussion
This paper describes our experience of seeking ethics
approval for a Canadian multicentre minimum risk
study (collecting anonymised data from hospital charts).
We found a similarly “muddled Canadian landscape” to
that described by Silversides for clinical trials [6]. In that
report, the complexity found in review of invasive inter-
ventions includes lack of standardization of ethics
review, lack of cooperation between REBs and differing
privacy legislation [1,6]. In our study, we found that
much duplication and additional work was required by
sites and the CPN Co-ordinating Centre, causing signifi-
cant delays before the CPN study was finally approved
in all 16 participating sites, even though 10 REBs had
only minor comments on the protocol.
The time, effort and cost of obtaining multiple ethics
approvals have been highlighted by a number of authors.
The resources consumed (by form filling and responding
to questions from REB) add to the cost of research
[4,14-16], and can delay both the initiation and comple-
tion of the research. The result of is an overall decrease
in the amount of research undertaken, a cost borne by
institutions and society more generally [14]. A high bur-
den of the cost and effort is specifically borne by the
REBs, including the paid REB staff and the volunteer
members of the REBs who conduct the reviews and
debate the ethics of studies [5,14].
Table 1 Standard elements covered on REB applications




Signature of department head or supervisor 7 (44%)
Checklist of documents 7 (44%)
Study Methods
Multicentre 10 (63%)
Study Design 9 (56%)
Location of research 12 (75%)
Description of procedures 9 (56%)
How outcomes measured 4 (25%)
Subjects
Normal subjects enrolled? 4 (25%)
Inclusion/exclusion criteria 12/11 (75, 69%)
Risks 10 (63%)
Benefits 10 (63%)
Time required of subject 4 (25%)




General description of privacy/confidentiality
measures
6 (38%)
Conflict of interest 6 (38%)
Research staff credentials 6 (38%)
Independent peer review? 5 (31%)
Budget
Fee for Service Payment details with sponsor 6 (38%)
Budget Details Requested 11 (68%)
Resource implications for hospital 4 (25%)
Table 2 Specific questions relevant to databases
Question No. (%) of the 16
sites
Identifying information used in stored data or in
analysis?
4 (25%)
How is identity of subjects protected? 7 (44%)
Password protection for data? 2 (13%)
Is information going into a database? 5 (31%)
Are data linked? 5 (31%)
Does anyone outside site have access to data? 5 (31%)
Data monitoring procedures 5 (31%)
Who will analyze the data? 5 (31%)
Disposition of data at end of study 8 (50%)
Plans for future use of the data 5 (31%)
Privacy risks and controls assessment 3 (19%)
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Despite the cost of duplication of ethics review for
researchers and REBs, there is no evidence that more
review leads to either more ethical research, or greater
patient safety [2]. Our study offers an insight to this
argument: despite the delays caused as a result of insti-
tutional review, our study protocol was eventually
adopted without substantive changes in all 16 sites.
Indeed, our study highlights the types of queries that
cause delays: REB procedural enquiries related to
incomplete application forms, concern about the quality
of the science, privacy issues and limited institutional
resources. Unfortunately our study was a retrospective
review of the ethics approval process, and we are unable
to accurately determine the contribution that each
aspect of review made towards the overall delays in
receiving study approval.
Qualitative research involving interviews with investi-
gators provides particular insight into the ethics review
process, pointing out that ethics review can be divided
into two integrated components: procedural issues, such
as form design, checking for incomplete applications or
consent forms; and ethics review proper [14,17]. It is
important to remember that perceived flaws in the REB
process cannot always be attributed to problems with
the ethics review itself [15]. The procedural issues are
generally what cause lack of trust and deterioration of
relationships between researchers and REBs [14-18], and
investigators may contribute significantly to delays in
the review process. Many investigators consider ethics
review itself to be positive, protecting the researchers as
well as patients [2,15]. In fact, the ethical considerations
seemed fairly similar between REBs in the CPN sites,
underpinned by common ethical principles detailed in
the TCPS in Canada [3]. In FDA inspections of REBs,
the majority of citations are for procedural inconsis-
tences, with few highlighting poor review of ethics [18].
It seems likely that differences between sites in proce-
dural processes contribute to preventing collaboration in
ethics review between sites [19].
Consensus exists that the ethics review should be pro-
portionate, seeking to expend most effort on higher risk
studies, with less deliberation devoted to studies consid-
ered to have no material ethical issues, or to involve
minimum risk to patients [3,14,20]. Unfortunately the
definition of lower risk is subjective, and it is this aspect
of ethics review that might further hamper collaboration
between REBs. In the case of CPN, collecting anon-
ymised data from hospital charts in 16 sites, privacy was
deemed the most significant concern, with REBs consis-
tently raising issues related to privacy and informed
consent. In particular, some REBs required assurance
that the CPN Co-ordinating Centre would not have
access to personal identifiers, although only five of the
15 standardized forms had questions specific to the
handling of data and procedures for ensuring confidenti-
ality. This could reflect differing roles of REBs in enfor-
cing privacy legislation in different provinces and may
indicate that privacy issues are evolving. Considerable
controversy exists among REB chairs regarding access to
medical records for research purposes [21].
The draft second edition of the TCPS recognizes the
dangers caused by delays from multiple reviews of mul-
ticentre studies, and highlights the threats to imple-
menting studies across institutions [22]. Several
solutions have been suggested to reduce the inefficiency
of local ethics review for multicentre studies. Centralised
(national or regional) REBs have been proposed
[17,23,24], offering the advantage of having a single
administrative (and ethics) system for investigators to
know and understand, and availability of specialised
expert reviewers [4,17]. A combination of central review
with local endorsement has also been suggested: this
allows for local circumstances to be taken into account
[23], but may lead to duplication of effort and causing
delays in implementing research [24,25]. A novel sug-
gestion by Nowak and colleagues, described a coordi-
nated approach to ethics review, using a web-based
program to promote communication between REBs
which are part of a collaborative REB network [23].
Such a system might well reduce duplication of ethics
review, but in order to succeed, a number of changes
would need to be mandated. A national accreditation
and regulatory system would be needed in any type of
centralised or coordinated approach, ideally incorporat-
ing operational changes to ensure consistency between
REB procedures [4,19,24,26,27]. To ensure consistency,
national training would be needed for REB staff and
committee members [4,19,24,27]. Unfortunately it will
be difficult to set standards for ethical debate and to
assess ethical decisions [26]. Only if REB accreditation
was accepted, would REBs be able to trust each others’
decisions, and accept approvals from other REBs [2,19].
The suggestions for centralised review will be unable to
take account of local resource availability and privacy
legislation that vary between provinces [6]. Québec has
moved to a centralized provincial system, like the
national system in the UK where local review boards
handle only site-specific issues [28]. An alternative
model, centralization by discipline, has been implemen-
ted by the Ontario Cancer Research Ethics Board; disci-
pline-specific boards allow for expertise to develop in a
specific area and for stakeholders to be involved in set-
ting standards [29]. This model will disadvantage multi-
disciplinary research that involves different medical
specialties.
Our results indicate that non-ethics review contribu-
ted significantly to the time taken to obtain ethics or
institutional approval. In order to understand the
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contribution of local privacy and resource availability
and review, detailed prospective studies are needed of
the approval processes for multicentre studies. Investiga-
tors and REBs should be willing to contribute to such
research that may lead to improvements in the review
process.
Despite challenges in seeking ethics review, strategies
exist to enhance collaboration between investigators and
REBs, and enhance the review process [5]. Investigators
should seek ethics training, particularly about the
national ethics guidelines (TCPS in Canada) [3]. They
should regard the REB members as advocates rather
than adversaries, working with the REB, using their
knowledge of the local REB system, privacy regulations,
and other institution-specific requirements [5]. By work-
ing closely in collaboration with the REB to provide all
the necessary information about their studies, the inves-
tigators will become local REB experts [5].
Conclusion
Although the REB process varied between CPN sites, all
REBs eventually approved the protocol without changes.
In the context of publicly funded research, such as the
CIHR-funded CPN, the additional delay and cost asso-
ciated with obtaining multicentre REB approval may
present an “unethical barrier” to potentially beneficial
research and cause harm through the guise of “protec-
tion” by discouraging minimal risk activities that could
improve care [4,30].
We believe that a critical examination of the ethical,
privacy and institutional review processes in Canada are
necessary, to explore their relative contribution to
research delays. Only by divorcing ethics from the other
types of more locally specific review could a centralised
system of ethics review be workable in the Canadian
context. CIHR and other funding agencies should exer-
cise leadership to ensure that new Canadian models of
multi-site ethics review are explored and implemented.
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